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10 years have passed since e-cigarettes were first marketed 
in the UK. Since then, e-cigarettes have engendered 
substantial controversy in the realms of public health and 
respiratory medicine.
The modern e-cigarette—the prototype Ruyan device, 
invented by Hon Lik in China in 2003—was designed to 
resemble a traditional cigarette and to deliver nicotine to 
the user via an inhalable aerosol. Since then, technological 
development of e-cigarettes has been exponential. By 2014, 
the USA alone had more than 460 e-cigarette brands, with a 
myriad of accessories and more than 7000 flavours of e-liquid 
available. Action on Smoking and Health (ASH) currently 
estimate that 2·8 million people in the UK use e-cigarettes. 
The e-cigarette market has developed from a handful of 
minor manufacturers to larger companies and mergers of 
companies, all developing their own products and brands. 
Investment in e-cigarettes from so-called big tobacco 
companies in the UK, especially since 2013, has aroused 
controversy. The Royal College of Physicians (RCP) report 
on e-cigarettes published in April, 2016, stressed concerns 
regarding the increasing involvement of big tobacco—a view 
shared by Robert West, Professor of Health Psychology at 
University College London (London, UK) and an expert on 
smoking cessation, who recently stated “we must view with 
considerable suspicion” the entry of the tobacco industry into 
the e-cigarette market. 
Despite several of the world’s leading tobacco companies 
claiming to be committed to tobacco harm reduction, many 
of them simultaneously refer to cigarettes and tobacco as 
their “core” business, products, or portfolio. As the RCP report 
points out regarding big tobacco interest in e-cigarettes, they 
“will remain a fraction of the market in tobacco products, 
with cigarettes remaining the dominant product category.” 
In January, 2016, the National Centre for Smoking Cessation 
and Training (NCSCT) pointed out that tobacco industry 
investment in e-cigarettes is predominantly related to first-
generation, “cig-a-like” devices, which are inefficient at 
delivering nicotine. In a longitudinal study, Hitchman and 
colleagues identified that both non-daily and daily use of 
such devices has negligible efficacy in smoking cessation. 
The RCP report questions whether tobacco industry interest 
and investment in these devices will merely perpetuate 
smoking and the dual use of e-cigarettes with tobacco via 
the “promotion of low-efficacy products that are likely to fail 
[as cessation aids] and hence minimise the threat to tobacco 
sales.”
The controversy surrounding e-cigarettes is not restricted 
to big tobacco involvement. The first UK television 
advertisement of e-cigarettes, aired in November, 2014, 
stimulated 1156 complaints, many of which raised concerns 
about the sexualised nature of the advert. The Advertising 
Standards Agency Regulations demanded that the advert 
should only appeal to adult smokers, but the language used 
by the young woman arguably targeted a far wider audience. 
Specifically, non-smoking adolescents could have been 
attracted to the explicitly sexualised imagery, language, and 
portrayal of coolness.
ASH have stated that the European Union’s Tobacco 
Products Directive, which came into force in the UK in May, 
2016, “is intended to introduce harmonised standards across 
the EU, improve the quality of products and reduce the risk 
of accidents, particularly in relation to children accidently 
drinking liquids or products leaking.” The Directive has 
been met with controversy, however, with Lord Callanan 
filing a motion to The House of Lords stating: “The Tobacco 
and Related Products Regulations [should] be annulled 
on the grounds that its restrictions on product choice and 
advertising of vaping devices were devised before evidence 
had accumulated that vaping was enabling many people to 
quit smoking”. A supporting online petition received more 
than 50 000 signatures. 
In May, 2016, The US Food and Drugs Agency (FDA) 
published its e-cigarettes regulations, regarding “the 
manufacture, import, packaging, labeling, advertising, 
promotion, sale, and distribution” of e-cigarettes. The 
e-cigarette industry and its advocates responded with claims 
that the regulation proposed would be unaffordable for the 
vast majority of businesses—except, controversially, big 
tobacco companies—and would hinder development and sale 
of new-generation devices which are allegedly increasingly 
effective at substituting smoking. The first lawsuit by a 
manufacturer was filed against the FDA only days later. 
The conflicting views on the efficacy of e-cigarettes to 
promote smoking cessation are at the centre of controversies 
surrounding their proposed harm reduction properties. In 
2014, David Nutt—Professor of Neuropsychopharmacology 
at Imperial College London (London, UK)—claimed that 
e-cigarettes had a potential effect on health care comparable 
to the success of antibiotics. Months earlier, smoking 
cessation experts had predicted that tobacco use could be 
eliminated in the UK within 5–10 years if e-cigarettes were 
allowed to flourish. However, despite the clear increase in 
marketing, development, and use of e-cigarettes in the 
UK, the number of users represents only a minority of adult 
smokers. Robert West—one of the predictors of tobacco use 
elimination—has since pointed out that if e-cigarettes were 
the  “game changer” many believed them to be, causing 
all smokers to switch from tobacco to e-cigarettes, “we 
might have expected to see a bigger effect than we have 
seen so far, which has actually been relatively small.” This 
discrepancy is probably due—at least in part—to the inferior 
speed of nicotine delivery and absorption from e-cigarettes 
compared with conventional cigarettes, as previously 
identified by Farsalinos and colleagues.
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Ultimately, as with any other proposed treatment relevant 
to respiratory medicine, we look towards systematic reviews 
to provide us with the best existing estimate of the efficacy 
of e-cigarettes in smoking cessation. The 2016 Cochrane 
review of e-cigarettes for smoking cessation identified only 
two randomised controlled trials (RCTs), just one of which 
included a comparison to nicotine replacement therapy. 
Meta-analysis of the data from these RCTs indicated 
that nicotine-containing e-cigarettes increased smoking 
cessation compared with nicotine-free e-cigarettes. The 
overall quality of evidence was graded as low due to a small 
number of underpowered trials and hence imprecision of 
the effect estimates. This review should be considered as 
insufficient evidence to guide clinical practice, particularly 
in light of the absence of trials comparing e-cigarettes to 
nicotine replacement therapy with health professional 
support. Linda Bauld of the University of Stirling (Stirling, 
UK) argues in her comment that more RCTs are needed, 
although a small number are ongoing. 
However, disagreement even exists around the 
appropriateness of RCTs to ascertain data on efficacy. 
Carl Phillips, former Scientific Advisor for the Consumer 
Advocates for Smoke Free Alternatives (CASSA), maintains 
that RCTs are a “bad study method” for e-cigarettes. This 
view, of course, contradicts commonly held views that such 
trials represent the gold-standard method for assessment of 
the efficacy of an intervention. 
Others have conducted meta-analyses in which RCTs and 
observational studies have been pooled together to derive 
a single estimate of the effect of e-cigarettes on smoking 
cessation. In a study published in The Lancet Respiratory 
Medicine, Kalkoran and Glantz reported reduced rates of 
smoking cessation with e-cigarettes in a meta-analysis of 
studies which varied methodologically. Their suggestion 
that e-cigarettes suppress the chances of successful smoking 
cessation opposed the Cochrane review findings, fuelling 
further controversy and dividing opinions on the efficacy of 
e-cigarettes in smoking cessation.
In an important, simultaneously published overview of 
the RCP report, four of its key members commented on 
the safety of e-cigarettes, stating that “e-cigarettes are 
unlikely to be harmless, and that long term use is likely to be 
associated with long term sequelae, including an increased 
risk of chronic obstructive pulmonary disease, lung cancer, 
possibly cardiovascular disease, and some other long term 
conditions associated with smoking.” In a 2015 review, 
Rowell and Tarran (University of North Carolina, Chapel 
Hill, NC, USA) discuss the potential for e-cigarettes to cause 
respiratory disease. Nicotine itself has been associated 
with risk of lung cancer; the thermal decomposition of the 
solvents used in e-cigarettes can produce carbonyls such as 
formaldehyde and acetaldehyde. Acrolein, another carbonyl, 
is strongly associated with the pathogenesis of COPD. 
Moreover, one of the flavouring additives used—diacetyl, 
which adds a buttery flavour—is potentially associated with 
risk of bronchiolitis obliterans. Indeed, the updated NCSCT 
guidance advises avoidance of e-liquids containing diacetyl, 
which has been found in many brands.
The RCP report, however, maintains that e-cigarettes 
remain significantly less harmful than the conventional 
cigarette, and cite the figure—as did Public Health England 
in 2015—that the “hazard to health arising from long-term 
use of e-cigarettes is unlikely to exceed 5% of the harm from 
smoking tobacco”. Opposing opinion comes from Robert 
Combes of Cavendish Consulting (UK) and Michael Balls of 
the University of Nottingham (Nottingham, UK). In their 
commentary, they argue that to postulate that e-cigarettes 
are a “low risk” product is, “in the light of current knowledge, 
a reckless and irresponsible suggestion.” They continue 
with the argument that the assertion of the RCP and Public 
Health England “ignores the possibilities that users might be 
repeatedly exposed to hitherto undetected contaminants 
and by-products, as well as to carcinogenic chemicals, or 
their precursors”. With the uncertainty surrounding both the 
effectiveness of e-cigarettes on smoking cessation and their 
safety, how are we in the health-care community placed 
to effectively discuss e-cigarettes with our patients and 
colleagues? The data are not currently available for users to 
make a fully informed choice on this issue. 
What is certainly true is that the controversies surrounding 
e-cigarettes are complex, multiple, and are not dissipating 
rapidly.
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